With a neutral sentiment as of May 8, 2025, according to Moneycontrol analysis, GlaxoSmithKline Pharmaceuticals demonstrates ...

GlaxoSmithKline Pharmaceuticals reported a 36% increase in net profit to Rs 263 crore in the March quarter, up from Rs 194 ...

GlaxoSmithKline Pharmaceuticals Ltd. reported a 36% increase in consolidated net profit to Rs 263 crore for the quarter ended ...

Todays focus will be on GSK Pharma shares in light of the companys announced topline growth and profitability for the full ...

8th May 2025 7:00 am RNS Transaction in Own Shares ...

Net Sales at Rs 966.08 crore in March 2025 up 6.06% from Rs. 910.87 crore in March 2024. Quarterly Net Profit at Rs. 260.14 ...

addKansai Nerolac Paints Ltd.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

ICICI Securities has raised its rating on GlaxoSmithKline Pharmaceuticals to Add from Hold with a new target price of Rs 2250. GSK Pharma's earnings are expected to see a CAGR of 15.3% over FY24-27.

India's GlaxoSmithKline Pharmaceuticals reported a higher fourth-quarter profit on Tuesday, led by steady demand for its ...

GlaxoSmithKline Pharmaceuticals reported a 36% rise in consolidated net profit to Rs 263 crore in the March quarter, driven by strong growth in its diversified portfolio. Revenue also increased to Rs ...

May 13 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported a higher fourth-quarter profit on Tuesday, led by steady demand for its generic drugs. The Indian unit ...